Skip to content
Review Open access

Syncytium-forming HSV-1 in cancer gene therapy: From molecular mechanisms to clinical translation

Sep 2026 · Virulence · Vol 17 · 0 citations · 117 references
Medicine

Abstract

ABSTRACT Gene therapy has emerged as a promising strategy for cancer treatment, yet challenges in efficient gene delivery remain a major barrier. Herpes simplex virus type 1 (HSV-1), as an oncolytic virus, has garnered attention for its potential in cancer therapy due to its replicative capacity, large genomic payload, and relatively low toxicity. Notably, syncytium-forming HSV-1 (SF-HSV-1) not only exhibits enhanced and sustained antitumor efficacy but also triggers profound immune responses. However, the exact molecular mechanisms orchestrating HSV-1-induced syncytium formation, its resulting cytotoxicity, and its precise role in immune modulation remain incompletely understood. This review aims to provide an in-depth exploration of the mechanisms underlying HSV-1 syncytium formation and its therapeutic implications in cancer gene therapy.

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.